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cost in the United States exceeding 1 billion dollars. Up to
17% of total spending for hemodialysis per patient per year
is associated with hemodialysis access–related morbidity.1,2
Repeated interventions to maintain access patency exact
an economic toll, and the physical and emotional tolls are
equally burdensome.
There is agreement that the ideal hemodialysis access
should be durable, have minimal risk of infection, and
require few interventions to maintain patency, but there is
significant controversy regarding which type of access
should ultimately be placed. Studies comparing long-term
and short-term performance of the two most common
types of hemodialysis access, autogenous arteriovenous fis-
tulas (AVFs) and prosthetic bridge grafts, have conflicting
results. A substantial number of studies have shown that
AVFs demonstrate superior overall patency and revision
rates compared with prosthetic access.2-5 Some investiga-
tors, however, have found that the early failure of autoge-
nous AVFs results in overall patency equivalent to
prosthetic grafts. The superior performance of autologous
access is not seen in all subgroups, particularly in elderly
The number of patients dependent on hemodialysis
has steadily increased, with an estimated 250,000 persons
in the United States currently requiring chronic hemodial-
ysis.1 Care of patients with end-stage renal disease has
considerable economic impact, with the estimated total
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Objective: The study’s aim was to evaluate access patency and incidence of revisions in patients initiating hemodialysis
and to determine differences in access performance by type of access among patient subgroups.
Methods: The study used data from the United States Renal Data System Dialysis Morbidity and Mortality Study Wave
2, which contained a random sample of dialysis patients initiating dialysis in 1996 and early 1997. Failures and revi-
sions were evaluated among 2247 newly placed hemodialysis accesses by using Cox proportional hazards regression
model and Poisson regression. Primary and secondary patency rates were estimated using the Kaplan-Meier method.
Results: Fifteen hundred seventy-four prosthetic grafts, 492 simple autogenous fistulas, and 181 venous transposition
fistulas were available for evaluation. Prosthetic grafts had a 41% greater risk of primary failure compared with simple
fistulas (relative risk, 1.41; 95% CI, 1.22-1.64; P < .001) and a 91% higher incidence of revision (relative risk, 1.91;
95% CI, 1.60-2.28; P < .001). At 2 years, autogenous fistulas demonstrated superior primary patency (39.8% versus
24.6%, P < .001) and equivalent secondary patency (64.3% versus 59.5%, P = .24) compared with prosthetic grafts.
When compared with simple fistulas, vein transpositions demonstrated equivalent secondary patency at 2 years (61.5%
versus 64.3%, P = .43) but inferior primary patency (27.7% versus 39.8%, P = .008) and had a 32% increased incidence
of revision (P = .04). Autogenous fistulas had superior primary patency compared with prosthetic grafts in all patient
subgroups except for patients with previously failed access. Vein transpositions showed the greatest benefit in terms of
patency and incidence of revision in women and in patients with previously failed access.
Conclusions: The preferential placement of autogenous fistulas may increase primary patency and decrease the incidence
of revisions. Vein transpositions had similar secondary patency compared with simple fistulas, but required more revi-
sions. The greatest benefit of a vein transposition fistula was seen in women and in patients with a history of access
failure. (J Vasc Surg 2001;34:694-700.)
and diabetic patients.6-8 Vein transpositions represent an
alternative method of autogenous access creation.9 Several
investigators have shown that vein transpositions are a reli-
able access alternative for hemodialysis, with patency rates
comparable with those of historical simple AVFs.10,11
However, there are few data regarding which patients are
most likely to benefit from creation of a venous transposi-
tion fistula.
Less than 30% of the accesses placed in the United
States are autogenous fistulas. Evidence supporting the
use of autogenous rather than prosthetic conduit has lead
many researchers to advocate strategies to reverse the
trend toward increased use of synthetic hemodialysis
access.2,12,13 Recommendations published by the National
Kidney Foundation Dialysis Outcome and Quality
Initiative (DOQI) in 1997 included goals that a minimum
of 50% of new accesses placed be autogenous fistulas and
that patients with failed access be reevaluated for con-
struction of an autogenous access.14 However, it is not
clear whether simple fistulas, vein transposition fistulas,
and prosthetic hemodialysis accesses perform similarly
among all subgroups of patients. We used data from the
United States Renal Data System to identify factors that
influence access patency and incidence of access revision
and to determine if there are identifiable groups of
patients in whom the placement of autogenous conduits is
particularly advantageous.
METHODS
Patient population and data collection. The study
used the database from the United States Renal Data
System Dialysis Morbidity and Mortality Study Wave 2,15
a true prospective study that contains a random sample of
4065 incident-hemodialysis and peritoneal-dialysis
patients initiating dialysis in 1996 or early 1997 at 799
dialysis facilities. For the purposes of this study, peritoneal-
dialysis patients (n = 2168) and patients in whom follow-
up data were not available (n = 314) were excluded,
leaving 1583 hemodialysis patients and 2247 hemodialysis
accesses available for analysis. Follow-up time ranged from
1 day to 3 years, with a mean follow-up time of 340 days.
Variables we abstracted included patient sex, age, race
(African American, white, other), smoking history (never,
previous, current), history of diabetes, access type (pros-
thetic graft, simple AVF, or venous transposition AVF),
and history of previous access. Longitudinal follow-up on
access failure or revision was determined via the Wave 2
database until completion of the study (9-12 months).
Access survival after the completion of Wave 2 was deter-
mined by identifying procedural codes for vascular access
failure and revision in the Medicare Part B claims records
that are part of the US Renal Data System database.
Procedures of interest were identified using current pro-
cedural terminology codes and were deemed reliable only
if the Medicare Part B claims records listed a monetary
reimbursement for the filing physician. Until January
2000, no specific current procedural terminology codes
for autogenous vein transposition existed. The code used
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for abstracting vein transpositions in this database was for
“creation of arteriovenous fistula by other than direct arte-
riovenous anastomosis, autogenous graft”.
Analysis. Time to primary access patency was defined
as the length of time between access placement and either
permanent failure or first revision requiring a procedure to
restore or maintain patency. An access revision was consid-
ered to have occurred when the access failed or when a
code identifying thrombectomy, thrombolysis, angioplasty,
or major revision was found. Time to secondary access
patency was defined as the length of time between access
placement and permanent failure of the access. Access fail-
ure was considered to have occurred when a new vascular
access was created or when a venous hemodialysis catheter
was inserted. Accesses were censored if the patient died or
had a transplant with a patent access, reached the end of
the study with a patent access (December 31, 1997),
stopped dialysis, or was lost to follow-up.
Primary and secondary graft patency rates were ana-
lyzed by using the Kaplan-Meier method with log-rank
testing to compare patency between groups. Univariate
and multivariate analyses of factors associated with primary
and secondary access failure were performed by using Cox
proportional hazards models. Poisson regression was used
to analyze the total number of revisions per access.
Adjustment variables were included in the multivariate
models if it was a priori believed that they might confound
the relationship between access type and outcome or if
they were found to be associated with outcome alone via
exploratory data analyses. Because of the clustered nature
of the data (multiple accesses per person), robust standard
errors were used when forming confidence intervals and
obtaining P values.
To ascertain whether access types performed similarly
in different subgroups of patients, an analysis was per-
formed comparing patency and incidence rate of revision
between prosthetic grafts and simple AVFs, venous trans-
positions and simple AVFs, and venous transpositions and
Table I. Patient characteristics
Characteristic n
Demographics
Mean age (y) (± SD) 66.0 (± 15)
Male 1182 (52.6%)
African American 762 (33.9%)
Comorbidities
Presence of diabetes 1211 (53.9%)
Smoking history
Nonsmoker 1258 (56.0%)
Former smoker 683 (30.4%)
Current smoker 306 (13.6%)
Operative details
First access 1566 (69.7%)
Type of access
Prosthetic graft 1574 (70.0%)
Simple autogenous fistula 492 (21.9%)
Venous transposition fistula 181 (8.1%)
prosthetic grafts among distinct patient subgroups. These
subgroups included age (>66 years old versus <66 years
old, the median population age), sex, race (African
American versus non–African American), history of dia-
betes, and history of access failure. Statistical analysis was
performed using SPSS (SPSS Inc, Chicago, Ill), STATA
(StataCorp, College Station, Tex), and S Plus (MathSoft,
Seattle, Wash).
RESULTS
Population characteristics. Table I displays charac-
teristics of the study population. During the study period,
2247 hemodialysis accesses were placed. These accesses
consisted of 1574 prosthetic grafts (70%), 492 simple
AVFs (21.9%), and 181 venous transpositions (8.1%).
Primary patency. At 1 and 2 years, primary patency
rates for simple AVFs were 56.1% and 39.8%, compared
with 38.2% and 24.6% for synthetic grafts (P < .001).
When compared with simple fistulas, venous transposi-
tions demonstrated inferior primary patency with rates of
43.5% at 1 year and 27.7% at 2 years (P = .008).
Factors that were associated with primary access failure
are shown in Table II. After adjustment for age, race, his-
tory of previous access placement, diabetes, and access
type, it was estimated that the risk of primary access failure
was 18% greater in women than in men (relative risk [RR],
1.18; 95% CI, 1.05-1.32; P = .004). African Americans
had an estimated 14% increase in the risk of primary access
failure when compared with non–African Americans (RR,
1.14; 95% CI, 1.01-1.28; P = .032). A history of access
failure was associated with an 81% increase in risk of pri-
mary access failure (RR, 1.81; CI, 1.60-2.05; P < .001).
The relationship between diabetes and risk of primary
access failure was marginally significant (P = .11). Diabetic
patients were estimated to have a 10% increase in risk of
primary access failure (RR, 1.10; 95% CI, 0.98-1.23). Age
was not found to be significantly associated with primary
access failure. The risk of primary access failure associated
with venous transposition fistulas was not found to be sig-
nificantly different from that of simple AVFs (RR, 1.13;
95% CI, 0.89-1.44; P = .33); however, prosthetic grafts
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were associated with a 41% increase in risk of primary fail-
ure compared with simple AVFs (RR, 1.41; 95% CI, 1.22-
1.64; P < .001).
Secondary patency. At 1 and 2 years, secondary
patency rates for simple AVFs were 73.2% and 64.2%, com-
pared with 71.8% and 59.5% for synthetic grafts, showing
no statistical difference (P = .24). Likewise, venous trans-
positions demonstrated similar secondary patency com-
pared with simple AVFs, with secondary patency rates of
67.9% at 1 year and 59.5% at 2 years (P = .43).
Table III displays the RR of secondary access failure
associated with sex, race, previous access placement, dia-
betes, and access type. After adjustment for these covari-
ates, the association between race and access failure was
marginally significant (P = .084). African American
patients were 14% more likely to have permanent access
failure than non–African American patients (RR, 1.14;
95% CI, 0.98-1.31). Patients with a history of failed access
had 2.56 times the risk of failure compared with patients
with a first access (RR, 2.56; 95% CI, 2.15-3.04; P <
.001). Sex and diabetes were not associated with an
increased risk of secondary access failure. The relationship
between access type and the risk of access failure was not
constant across age (P < .001 for the age-access type inter-
action). The risk of secondary access failure comparing
venous transposition fistulas with simple AVFs decreased
with increasing age. In patients younger than 60 years, the
risk of secondary access failure was estimated to be greater
with venous transposition fistulas than with simple AVFs.
In contrast, simple AVFs were associated with an increased
risk of access failure when compared with venous transpo-
sition fistulas in patients older than 60 years. Similarly, a
comparison of prosthetic grafts with simple AVFs revealed
that as patient age increased, the RR of secondary pros-
thetic access failure decreased.
Revisions. A total of 2582 access revisions occurred
in the study period. There were no differences in incidence
of revision between sexes, history of diabetes, or by age
(Table II). African American patients had a greater inci-
dence of revision of 14% compared with non–African
American patients (incidence rate ratio [IRR], 1.14; 95%
Table II. Multivariate analysis of factors associated with risk of primary access failure and incidence rate of access revision*
Primary patency Access revision
Covariate aRR (95% CI) P value aIRR (95% CI) P value
Age (10 y) 1.01 (0.97-1.05) .616 1.01 (0.96-1.06) .671
Sex (female vs male) 1.18 (1.05-1.32) .004 1.02 (0.89-1.16) .827
Race (African American vs non–African American) 1.14 (1.01-1.28) .032 1.14 (1.00-1.31) .057
Previous accesses placed (yes vs no) 1.81 (1.60-2.05) <.001 1.83 (1.60-2.10) <.001
Diabetes (yes vs no) 1.10 (0.98-1.23) .112 1.10 (0.96-1.25) .167
Access type <.001 <.001
Simple autogenous fistula 1.0 1.0
Venous transposition fistula 1.13 (0.89-1.44) .326 1.32 (1.01-1.72) .041
Graft 1.41 (1.22-1.64) <.001 1.91 (1.60-2.28) <.001
*Adjusted for age, sex, race, previous access placement, diabetes, and access type.
aRR, Adjusted relative risk; aIRR, adjusted incident rate ratio.
CI, 1.00-1.31; P = .057) The rate of revision in patients
with previous access failure was estimated to be 83%
higher than in patients with a first access (IRR, 1.83; 95%
CI, 1.60-2.10; P < .001). Compared with simple AVFs,
vein transposition fistulas had a 32% higher incidence of
revisions (IRR, 1.32; 95% CI, 1.01-1.72; P = .04),
whereas prosthetic grafts had a 91% higher incidence of
revision (IRR, 1.91; 95% CI, 1.60-2.28; P < .001).
Subgroup analysis. The results of a subgroup analy-
sis are presented in Figs 1, 2, and 3.
Fig 1, A graphically depicts the performance of pros-
thetic grafts compared with simple AVFs with respect to
primary patency across subgroups defined by age, sex,
race, previous access placement, and diabetes. Simple
AVFs outperformed grafts in every subgroup. In patients
without diabetes, the risk of primary failure was 68%
higher in prosthetic grafts compared with simple AVFs
(RR, 1.68; 95% CI, 1.40-2.10), whereas in patients with
diabetes, this increase in risk of failure was only 19% (RR,
1.19; 95% CI, 1.00-1.40). The RR associated with pri-
mary access failure was similar when comparing all other
patient subgroups.
Fig 1, B displays a comparison of grafts with simple fis-
tulas with respect to access revision. Simple AVFs outper-
formed prosthetic grafts in every subgroup. In men, grafts
were associated with a 2.24-fold increase in the rate of
access revision (IRR, 2.24; 95% CI, 1.8-2.8), whereas in
women this increase in risk was estimated to be 1.45-fold
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(IRR, 1.45; 95% CI, 1.1-1.9). The rate of revision associ-
ated with prosthetic grafts in nondiabetic patients was esti-
mated to be 2.55-fold greater than the rate of revision
associated with simple AVFs (IRR, 2.55; 95% CI, 1.9-
3.3). In diabetic patients, the rate of revision associated
with prosthetic grafts was 49% higher than the rate associ-
ated with the simple AVFs (IRR, 1.49; 95% CI, 1.2-1.9).
Subgroup analysis results comparing venous transposi-
tion fistulas with simple AVFs with respect to the risk of
primary access failure and the rate of access revision are
displayed in Figures 2, A and 2, B, respectively. In patients
with a first access, the risk of primary failure was estimated
to be 1.55 when comparing venous transposition fistulas
with simple AVFs (RR, 1.55; 95% CI, 1.2-2.1), whereas in
patients with a past access failure, venous transpositions
outperformed simple fistulas (RR, 0.71; 95% CI, 0.5-1.1).
There were no other significant differences when compar-
ing the performance of venous transpositions with that of
simple AVFs with respect to primary access failure among
subgroups. The largest differences in the impact of access
type on the rate of access revision were seen between sexes
and in patients with and without history of access. The
rate of revision associated with venous transpositions in
male patients was estimated to be 72% greater than the
rate of revision associated with simple AVFs (IRR, 1.72;
95% CI, 1.2-2.5). In women, the rate of revision associ-
ated with grafts was estimated to be 15% lower than the
rate associated with simple AVFs (IRR, 0.85; 95% CI, 0.6-
Table III. Multivariate analysis of factors associated with risk of secondary access failure
Covariate aRR (95% CI)* P value
Sex (female vs male) 1.08 (0.94-1.24) .298
Race (African American vs non–African American) 1.14 (0.98-1.31) .084
Previous accesses placed (yes vs no) 2.56 (2.15-3.04) <.001
Diabetes (yes vs no) 1.11 (0.97-1.28) .134
Access type†
Patient age, 30 y
Simple autogenous fistula 1.0
Venous transposition fistula 2.68 (1.41-5.12) .003
Graft 1.32 (0.85-2.03) .216
Patient age, 40 y
Simple autogenous fistula 1.0
Venous transposition fistula 1.90 (1.16-3.11) .011
Graft 1.18 (0.85-1.64) .318
Patient age, 50 y
Simple autogenous fistula 1.0
Venous transposition fistula 1.34 (0.92-1.95) .123
Graft 1.06 (0.84-1.35) .621
Patient age, 60 y
Simple autogenous fistula 1.0
Venous transposition fistula 0.95 (0.69-1.31) .746
Graft 0.95 (0.79-1.16) .633
Patient age, 70 y
Simple autogenous fistula 1.0
Venous transposition fistula 0.67 (0.46-0.97) .035
Graft 0.86 (0.69-1.07) .165
*Referent group is simple AVF. RRs are adjusted for age, sex, race, previous access placement, diabetes, and access type.
†Interaction between age and access type significant at P < .001.
aRR, Adjusted relative risk.
1.2). In patients without previous access placement, the
rate of revision associated with venous transposition fistu-
las was 59% greater than the rate of revision of simple
AVFs (IRR, 1.59; 95% CI, 1.2-2.2). Conversely, in
patients with a history of access placement, venous trans-
position fistulas decreased the rate of access revision by
16% when compared with simple AVFs (IRR, 0.84; 95%
CI, 0.5-1.4).
DISCUSSION
Our data demonstrate that in the study population
overall, the performance of simple AVFs was superior to
those of prosthetic grafts and vein transpositions. Primary
patency was superior in simple AVFs at 1 and 2 years, and
the RR of failure was lowest with simple AVFs in multi-
variate regression analysis. We saw no difference in sec-
ondary patency between simple AVFs, prosthetic grafts,
and vein transpositions in our Kaplan-Meier survival analy-
sis. Multivariate regression adjusting for sex, age, race, dia-
betes status, and access history demonstrates that the risk
of permanent access failure of each type of access varies
with the patient’s age. Younger patients showed the great-
est benefit of simple AVFs, whereas in patients older than
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70 years, venous transpositions actually had the best sec-
ondary patency. An additional benefit of simple AVFs was
a decreased incidence rate of revision to maintain access
patency compared with simple fistulas to prosthetic grafts
and vein transpositions. The percentage of autogenous
access placed (30%) was significantly lower than recom-
mended by DOQI guidelines; however, we found that
autogenous access was beneficial only in certain patient
subgroups. The differential performance of autogenous
access in patients with different risk factors for failure may
make achievement of DOQI goals difficult in some patient
populations.
Our data demonstrate that vein transpositions only
show superior performance in select populations. The per-
formance of vein transpositions in this population was
poorer than that reported in other series.6,11,12,16 There
are several possible reasons for our differing results. The
previous studies were smaller, conducted on select popu-
lations, and did not compare prosthetic grafts, vein trans-
positions, and simple AVFs in a single study population,
resulting in difficulties generalizing previous results to the
general population of dialysis patients. It is also possible
that some vein transposition fistulas may have been mis-
Fig 1. Subgroup estimates comparing prosthetic grafts with simple fistulas regarding (A) the risk of primary access failure and (B) the
rate of access revision.
Fig 2. Subgroup estimates comparing venous transposition fistulas with simple fistulas regarding (A) the risk of primary access failure
and (B) the rate of access revision.
A B
A B
coded in the USRDS database. Finally, vein transposition
fistulas were more likely to be placed in patients with a his-
tory of access (10.1% versus 7.2%; P = .02), suggesting
that transposition fistulas are placed in patients already at
higher risk of access dysfunction.
Although in 1997 51% of the incident chronic
hemodialysis population were older than 65 years, place-
ment of autogenous fistulas in older patients is controver-
sial. Most investigators have found that autogenous
fistulas have poorer patency rates in older patients.6 Our
data demonstrate that patient age had no effect on pri-
mary patency or incidence of access revision. In our sub-
analysis, both simple AVFs and vein transpositions had
superior primary patency and decreased incidence of revi-
sions than did prosthetic grafts in patients older than 66
years. Vein transpositions and simple AVFs had equivalent
primary patency and incidence of revisions in this group.
Because most vein transpositions are constructed in the
upper arm, these data agree with a recent paper by
Berardinelli and Vegeto,16 who suggest that upper-arm fis-
tulas may be the access of choice in older patients. In con-
trast, patients in our younger age group had superior
primary patency with simple AVFs and a decreased inci-
dence of access revision with simple AVFs and vein trans-
positions compared with prosthetic grafts. Clearly,
autogenous access should be used preferentially in
younger patients with end-stage renal disease.
Little is known about the ideal access type in women.
Investigators have found that patency of autogenous
access in women is inferior to that in men18 and that
female sex is an independent risk factor for access-related
hospitalization.19 In our population, women were signifi-
cantly less likely to have an autogenous access than were
men. Overall, the women in our population had inferior
primary access patency but equivalent secondary patency
and incidence of revision when compared with men. In
both sexes, simple AVFs had superior primary patency and
decreased incidence of revision compared with vein trans-
positions and prosthetic grafts. However, in women, vein
transpositions were clearly superior to prosthetic grafts
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and equivalent to simple AVFs in terms of primary patency
and incidence of revisions.
Non–African Americans had significantly better pri-
mary patency and fewer revisions than did African
American patients across all access types, consistent with
data from other authors showing that African American
patients have a higher rate of hospitalization for access-
related morbidity.19 African Americans in our study were
significantly less likely to have an autogenous access com-
pared with non–African Americans. The reason for the
poor outcome of hemodialysis access in the African
American population is not readily apparent, but could
possibly be related to an increased percentage of pros-
thetic access, differences in access to health care, or differ-
ences in vascular biology such as the development of
intimal hyperplasia.
Fully 30% of the patients required a second access to be
placed during the relatively short study period. Previous
access failure imparted a 1.8-fold increase in risk of primary
access failure, a 2.6-fold risk of secondary access failure, and
a 1.8-fold increase in incidence of access revision.
Interestingly, patients with a history of access failure
demonstrated no difference in primary patency when com-
paring simple AVFs and prosthetic grafts, but vein transpo-
sitions had clearly superior primary patency and decreased
incidence of access revision compared with prosthetic grafts
and simple AVFs. The reason for the advantage of vein
transposition fistulas in this population is not inherently
obvious, but patients with previously failed access may have
already used their forearm veins or had poor forearm veins
to begin with and, as such, be poor candidates for a second
access using forearm veins or the upper arm cephalic vein.
The basilic vein, often used in venous transpositions, is deep
and less often used for intravenous access or for hemodialy-
sis access. The basilic vein is of adequate quality and caliber
for access creation in 95% of patients.5 It may, therefore,
represent the ideal access conduit in patients in whom sim-
ple AVFs or prosthetic grafts have failed.
This study had several limitations. The retrospective
nature may limit the applicability of some of our conclu-
Fig 3. Subgroup estimates comparing prosthetic grafts with venous transposition fistulas regarding (A) the risk of primary access fail-
ure and (B) the rate of access revision.
A B
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sions; however, our data are in agreement with those of
numerous other studies in finding that autogenous fistulas
demonstrate superior patency as compared with prosthetic
grafts. Another limitation of this study is the short follow-
up time. This diminishes the validity of our findings for
secondary access patency. Although there are several limi-
tations, this is the first large population-based study to
identify factors associated with patency and revisions
among hemodialysis access types—prosthetic grafts, sim-
ple autogenous fistulas, and venous transpositions. In
addition, as a population-based study, the results are gen-
eralizable to the dialysis population as a whole and are not
a reflection of unit-specific or surgeon-specific practices.
CONCLUSIONS
Although our data would suggest that simple autoge-
nous fistulas are the access of choice when evaluating our
population as a whole, these results are not generalizable
to all patient groups. Sex, race, access history, and age may
all have an impact on access survival and may also influ-
ence the availability of usable veins for the creation of
autogenous access. Men, non–African Americans, and
patients with a first access appreciated the greatest benefit
from simple autogenous fistulas. Vein transposition fistulas
had the greatest advantage in elderly patients, in women,
and particularly in patients with a history of failed access.
The ideal access for a patient must be individualized
according to which access type would be most durable and
require the least number of revisions.
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